88 related articles for article (PubMed ID: 11727626)
21. Effect of postoperative 131I treatment on thyroglobulin measurements in the follow-up of patients with thyroid cancer.
Baskin HJ
Thyroid; 1994; 4(3):239-42. PubMed ID: 7833657
[TBL] [Abstract][Full Text] [Related]
22. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients.
Baudin E; Do Cao C; Cailleux AF; Leboulleux S; Travagli JP; Schlumberger M
J Clin Endocrinol Metab; 2003 Mar; 88(3):1107-11. PubMed ID: 12629092
[TBL] [Abstract][Full Text] [Related]
23. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin.
Malandrino P; Latina A; Marescalco S; Spadaro A; Regalbuto C; Fulco RA; Scollo C; Vigneri R; Pellegriti G
J Clin Endocrinol Metab; 2011 Jun; 96(6):1703-9. PubMed ID: 21450986
[TBL] [Abstract][Full Text] [Related]
24. Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer.
Carril JM; Quirce R; Serrano J; Banzo I; Jiménez-Bonilla JF; Tabuenca O; Barquín RG
J Nucl Med; 1997 May; 38(5):686-92. PubMed ID: 9170428
[TBL] [Abstract][Full Text] [Related]
25. [Thyroglobulin, 131I-whole body scintigraphy and risk factors in the follow-up of differentiated thyroid cancer].
Berding G; Hüfner M; Georgi P
Nuklearmedizin; 1992 Feb; 31(1):32-7. PubMed ID: 1561118
[TBL] [Abstract][Full Text] [Related]
26. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
[TBL] [Abstract][Full Text] [Related]
27. Follow-up study of postoperative patients with thyroid cancer by thallium-201 scintigraphy and serum thyroglobulin measurement.
Iida Y; Hidaka A; Hatabu H; Kasagi K; Konishi J
J Nucl Med; 1991 Nov; 32(11):2098-100. PubMed ID: 1941144
[TBL] [Abstract][Full Text] [Related]
28. Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans.
Clark OH; Hoelting T
Thyroid; 1994; 4(4):501-5. PubMed ID: 7711516
[TBL] [Abstract][Full Text] [Related]
29. Radioiodine total body scan versus serum thyroglobulin levels in follow-up of patients with thyroid cancer.
Colacchio TA; LoGerfo P; Colacchio DA; Feind C
Surgery; 1982 Jan; 91(1):42-5. PubMed ID: 7034259
[TBL] [Abstract][Full Text] [Related]
30. Follow-up of differentiated thyroid cancer.
Pacini F
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
[TBL] [Abstract][Full Text] [Related]
31. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
32. Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results?
Ma C; Xie J; Kuang A
J Nucl Med; 2005 Jul; 46(7):1164-70. PubMed ID: 16000286
[TBL] [Abstract][Full Text] [Related]
33. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma.
Muratet JP; Giraud P; Daver A; Minier JF; Gamelin E; Larra F
J Nucl Med; 1997 Sep; 38(9):1362-8. PubMed ID: 9293788
[TBL] [Abstract][Full Text] [Related]
34. Overview of the management of differentiated thyroid cancer.
Fernandes JK; Day TA; Richardson MS; Sharma AK
Curr Treat Options Oncol; 2005 Jan; 6(1):47-57. PubMed ID: 15610714
[TBL] [Abstract][Full Text] [Related]
35. Thyroglobulin in patients with differentiated thyroid carcinoma.
Lindegaard MW; Paus E
Scand J Clin Lab Invest Suppl; 1991; 206():79-84. PubMed ID: 1947763
[TBL] [Abstract][Full Text] [Related]
36. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation.
Phan HT; Jager PL; van der Wal JE; Sluiter WJ; Plukker JT; Dierckx RA; Wolffenbuttel BH; Links TP
Eur J Endocrinol; 2008 Jan; 158(1):77-83. PubMed ID: 18166820
[TBL] [Abstract][Full Text] [Related]
37. Thallium-201 and iodine-131 scintigraphy in differentiated thyroid carcinoma.
Lorberboym M; Murthy S; Mechanick JI; Bergman D; Morris JC; Kim CK
J Nucl Med; 1996 Sep; 37(9):1487-91. PubMed ID: 8790199
[TBL] [Abstract][Full Text] [Related]
38. Serum thyroglobulin in the management of patients with thyroid cancer.
Barsano CP; Skosey C; DeGroot LJ; Refetoff S
Arch Intern Med; 1982 Apr; 142(4):763-7. PubMed ID: 7073416
[TBL] [Abstract][Full Text] [Related]
39. Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors.
Leboeuf R; Emerick LE; Martorella AJ; Tuttle RM
Thyroid; 2007 Jun; 17(6):543-7. PubMed ID: 17614775
[TBL] [Abstract][Full Text] [Related]
40. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
